[10/3/2025] Today, the U.S. Food and Drug Administration (FDA) is announcing a new pilot prioritization program for the review of abbreviated new drug applications (ANDAs) that aims […]

On October 2, 2025, the Food and Drug Administration approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals, Inc.) in combination with atezolizumab (Tecentriq, Genentech Inc.) or atezolizumab and hyaluronidase-tqjs […]

en Español [10-2-2025] FDA continues to advise consumers not to purchase or use the Kuka Flex Forte product. FDA laboratory analysis confirmed Kuka Flex Forte sold on […]

Image By: George Tidmarsh, M.D., Ph.D., Director, Center for Drug Evaluation and Research Like all drugs, sunscreens must meet rigorous standards for safety and efficacy. Because […]

Delivery Method: VIA UNITED PARCEL SERVICE AND VIA E-MAIL Reference #: 25-HFD-45-09-03 Product: Drugs Recipient: Pamela K. Den Besten, DDS, MS 521 Parnassus AvenueRoom S612, Box […]

Delivery Method: VIA UNITED PARCEL SERVICE AND VIA E-MAIL Reference #: 25-HFD-45-09-02 Product: Drugs Recipient: Recipient Name Ralph A. DeFronzo, M.D. Recipient Title Department of Medicine, […]

[9-30-2025] The Food and Drug Administration is advising consumers not to purchase or use Me Vale Madre, a product promoted and sold for migraine and stress […]